The Dexcel Pharma-backed immunotherapy discovery technology developer’s latest round was led by Koch Disruptive Technologies and took its overall funding to $295m.
Koch Disruptive Technologies (KDT), a corporate venturing subsidiary of chemicals and energy conglomerate Koch Industries, led a $215m series B round for US-based biotech data provider Immunai yesterday.
Alexandria Venture Investments, the venture capital subsidiary of life sciences and property investment trust Alexandria Real Estate Equities, also took part in the round, as did Talos VC, 8VC, Piedmont, Icon and unnamed other investors that included existing shareholders.
Immunai is developing an artificial intelligence and machine learning-equipped clinical database with immunological…
